CARLSBAD, Calif. — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that positive results from the Phase 3 OASISplus prospective switch study of donidalorsen in patients with hereditary angioedema (HAE) were published in The Journal of Allergy and Clinical Immunology (JACI) In Practice. Results indicate that patients who switched to donidalorsen from prior...
Latest News
SAN DIEGO, Calif. – AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in both recurrent and newly diagnosed glioblastoma (GBM) patients when given in combination with standard-of-care radiotherapy and showed preliminary efficacy in recurrent GBM patients, according to results from a global phase I trial presented...
OSLO, Norway — New Investigational Drug Also Shown to Improve Remission Rates and Reduce Short-Term Mortality Compared to Previous Treatments Clavis Pharma ASA (OSE: CLAVIS) today announces positive final results from a Phase II trial of its novel investigational cancer drug, elacytarabine (CP-4055), in patients with late-stage acute myeloid leukaemia...
Lund Sweden – Active Biotech AB (publ) (NASDAQ STOCKHOLM: ACTI) and NeoTX today announced that they have received clearance from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application of the tumor targeted superantigen naptumomab estafenatox (Naptumomab). The Phase IIa open label trial will evaluate...
Barcelona, Spain – The Alliance for Clinical Trials in Oncology today announced final results will be presented at ESMO 2024 from CABINET (A021602), a phase III trial evaluating cabozantinib compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors...
NIJMEGEN, the Netherlands — Philikos B.V., a Dutch biotechnology company developing antibody-based therapies to treat severe immune disorders, today announced that it has enrolled the first patient in a Phase 1/2 clinical trial designed to evaluate the use of T-Guard for the treatment of patients with diffuse cutaneous systemic sclerosis...
MARLBOROUGH, Mass. — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that new preclinical data demonstrating the potential of INTASYL self-delivering siRNA targeting Cbl-b improves natural killer...
CORINTH — A local photographer and a family shattered by illness crossed paths Saturday to create lasting memories of 4-year-old Kaitlin Bowman. Photographer Tracey Buyce selected the Bowman family — Kaitlin and her parents, Becky and Jason — as winners of her version of a national photography contest called “Giving...
Approved as the first subcutaneous treatment for paroxysmal nocturnal hemoglobinuria (PNH) in Taiwan, applying Chugai’s proprietary Recycling Antibody Technology Approval based on data including COMMODORE 2 study, which demonstrated non-inferiority in efficacy of every four weeks subcutaneous PiaSky compared to intravenous eculizumab every two weeks in the maintenance dosing period...
Cambridge, MA – Studies at Picower Institute and elsewhere are producing mounting evidence that light flickering and sound clicking at the gamma brain rhythm frequency of 40 Hz can reduce Alzheimer’s disease (AD) progression and treat symptoms in human volunteers as well as lab mice. In a new study in Nature using a...